According to a recent report by Reuters, “Drugmaker GlaxoSmithKline plans to invest up to 130 million pounds ($216 million) in Africa over the next five years as chronic diseases become more common among the continent’s swelling urban middle classes.”
This article is for Premium Members only. Please login below to read the rest of this article.
Not a Premium Member yet? Become one today.